Please ensure Javascript is enabled for purposes of website accessibility

Why Co-Diagnostics Stock Is Dropping Today

By Prosper Junior Bakiny - Mar 29, 2021 at 4:09PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's recent struggles on the stock market continue.

What happened?

Shares of molecular diagnostics specialist Co-Diagnostics (CODX 0.40%) are dropping sharply on Monday and were down by 10.3% as of 3:01 p.m. EDT, after falling by as much as 12.4% earlier today. There was no company-specific news that caused the sell-off, but we can probably attribute Co-Diagnostics' losses on the market today to bearish commentary from a Wall Street analyst. 

So what

Maxim analyst Jason McCarthy downgraded Co-Diagnostics to hold from buy. For what reason? Last year, the company benefited immensely from its coronavirus-related efforts. Co-Diagnostics reported record fourth-quarter 2020 revenue of $27.1 million, largely thanks to its Logix Smart COVID-19 test. For the full fiscal year 2020, which ended on Dec. 31, 2020, the company's top line came in at $74.6 million, compared to the roughly $215,000 it reported during the fiscal year 2019.

Downward-bound graph on a blackboard.

Image source: Getty Images.

However, McCarthy believes that the growth the company's revenue experienced last year thanks to the sale of its coronavirus testing solutions has peaked. The analyst expects much less impressive revenue increases in the current fiscal year. McCarthy also believes Co-Diagnostics' success in the coronavirus testing market is already baked into its stock price.

Now what

While it's always wise to take analyst recommendations with a grain of salt, in my view, McCarthy is onto something. As more people worldwide receive vaccines for COVID-19, the need for test kits for the disease will decrease. And given that this market is highly competitive, these developments will hinder Co-Diagnostics' top-line growth in the short term as the company finds other ways to generate strong revenue. In the meantime, Co-Diagnostics stock will likely underperform the market. With this backdrop in mind, it might be best for investors to stay away from this healthcare stock for now.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Co-Diagnostics, Inc. Stock Quote
Co-Diagnostics, Inc.
$4.99 (0.40%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/22/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.